A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-Met co-expressing metastatic pancreatic adenocarcinoma

Study Overview

This study is being done to test if treatment with both cabozantinib and erlotinib has an effect on pancreatic cancer.

Study Description

The purpose of this study is to look at a novel combination of targeted agents in a biomarker-selected population of patients with pancreatic cancer.

Additional Information

Participants will not be paid for their participation.


  • IRB Number: 1705697788 (IUSCC-0597)
  • Research Study Identifier: TX8222
  • Principal Investigator: Patrick Loehrer, MD

Recruitment Status

Closed
Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.